CVS Stock Rises on Legal Storm as Trading Volume Surges 42.94% to Rank 163th

CVS (CVS) traded at a 0.86% gain on August 21, 2025, with a trading volume of $510 million, marking a 42.94% surge from the previous day and ranking 163rd in market activity. The stock’s performance followed renewed legal scrutiny as federal courts handed down two significant rulings against the pharmacy giant. In the first case, Judge Mitchell Goldberg tripled damages against CVS Caremark to $285 million under the False Claims Act, citing evidence of financially motivated overbilling practices. The ruling also included a $4.87 million civil fine, rejecting CVS’ request for a reduced penalty. A separate whistleblower lawsuit from 2024 further compounded pressure, with a $948 million judgment against its Omnicare unit for submitting 3.3 million false claims between 2010 and 2018.

Legal challenges persist as the U.S. Department of Justice continues its opioid crisis lawsuit against CVS, alleging violations tied to controlled substances and false claims. The company also faces a Federal Trade Commission investigation over alleged price manipulation in insulin and other drugs. Recent operational strains include announced layoffs of 2,900 employees and leadership changes following CEO Karen Lynch’s departure. These developments coincide with broader industry scrutiny of pharmacy benefit managers and rising regulatory pressures across the healthcare sector.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The CAGR was 6.98%, with a maximum drawdown of 15.59% during the backtest period. The strategy demonstrated steady growth over time, making it a robust choice for investors seeking consistent returns. However, the significant drawdown in mid-2023 highlights the importance of risk management, even in a seemingly stable strategy like this one.